Salveen Richter
Stock Analyst at Goldman Sachs
(2.33)
# 2,353
Out of 4,814 analysts
203
Total ratings
38.26%
Success rate
-2.4%
Average return
Main Sectors:
Stocks Rated by Salveen Richter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,019 → $917 | $563.16 | +62.83% | 10 | Apr 14, 2025 | |
| ADPT Adaptive Biotechnologies | Upgrades: Buy | $8 → $9 | $7.33 | +22.87% | 10 | Mar 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $36 → $32 | $18.17 | +76.11% | 8 | Mar 3, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $42 | $24.61 | +70.66% | 1 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $18 | $2.70 | +567.90% | 3 | Feb 27, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $66 → $57 | $37.76 | +50.95% | 3 | Feb 13, 2025 | |
| BIIB Biogen | Maintains: Buy | $281 → $245 | $118.61 | +106.56% | 3 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $85 → $96 | $104.53 | -8.16% | 5 | Feb 12, 2025 | |
| MRNA Moderna | Downgrades: Neutral | $99 → $51 | $24.73 | +106.27% | 10 | Jan 29, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $45 → $40 | $12.72 | +214.47% | 5 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $12 | $7.27 | +65.18% | 8 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $20 | $13.00 | +53.85% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $63 → $70 | $58.22 | +20.23% | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $198 → $370 | $234.75 | +57.61% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $76 | $35.64 | +113.24% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $33 → $37 | $28.32 | +30.65% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $11 | $7.44 | +47.95% | 11 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $53 | $27.66 | +91.61% | 9 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $313 → $350 | $277.29 | +26.22% | 7 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $81 | $3.06 | +2,547.06% | 3 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $442 → $559 | $489.10 | +14.29% | 4 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 | $4.98 | +0.40% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $5 | $12.25 | -59.18% | 5 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $188 → $215 | $53.79 | +299.70% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $6.83 | +61.17% | 1 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $31 | $1.45 | +2,037.93% | 7 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $257 → $225 | $259.54 | -13.31% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $1.24 | +1,681.38% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.43 | - | 4 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $5.00 | +500.00% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $14 | $0.89 | +1,474.80% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $5.50 | +63.64% | 6 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $3 | $1.25 | +140.00% | 4 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $15 → $12 | $14.71 | -18.42% | 8 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $1.64 | +265.85% | 3 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $39 → $43 | $46.87 | -8.26% | 1 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $40 → $60 | $4.15 | +1,345.78% | 6 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $3 → $2 | $1.43 | +39.86% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $125 → $100 | $6.16 | +1,523.38% | 1 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $28 | $7.90 | +254.65% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $28 → $30 | $0.31 | +9,454.14% | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $57 → $50 | $88.17 | -43.29% | 4 | Mar 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $11.21 | +301.43% | 1 | Mar 17, 2020 |
Regeneron Pharmaceuticals
Apr 14, 2025
Maintains: Buy
Price Target: $1,019 → $917
Current: $563.16
Upside: +62.83%
Adaptive Biotechnologies
Mar 21, 2025
Upgrades: Buy
Price Target: $8 → $9
Current: $7.33
Upside: +22.87%
Apellis Pharmaceuticals
Mar 3, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $18.17
Upside: +76.11%
Summit Therapeutics
Feb 28, 2025
Initiates: Buy
Price Target: $42
Current: $24.61
Upside: +70.66%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $2.70
Upside: +567.90%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Neutral
Price Target: $66 → $57
Current: $37.76
Upside: +50.95%
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $281 → $245
Current: $118.61
Upside: +106.56%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $85 → $96
Current: $104.53
Upside: -8.16%
Moderna
Jan 29, 2025
Downgrades: Neutral
Price Target: $99 → $51
Current: $24.73
Upside: +106.27%
Denali Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $12.72
Upside: +214.47%
Jan 14, 2025
Maintains: Neutral
Price Target: $20 → $12
Current: $7.27
Upside: +65.18%
Dec 12, 2024
Maintains: Neutral
Price Target: $9 → $20
Current: $13.00
Upside: +53.85%
Oct 30, 2024
Maintains: Neutral
Price Target: $63 → $70
Current: $58.22
Upside: +20.23%
Aug 16, 2024
Upgrades: Buy
Price Target: $198 → $370
Current: $234.75
Upside: +57.61%
Aug 2, 2024
Maintains: Buy
Price Target: $67 → $76
Current: $35.64
Upside: +113.24%
Aug 2, 2024
Maintains: Sell
Price Target: $33 → $37
Current: $28.32
Upside: +30.65%
Jul 26, 2024
Maintains: Neutral
Price Target: $19 → $11
Current: $7.44
Upside: +47.95%
Jun 4, 2024
Maintains: Neutral
Price Target: $33 → $53
Current: $27.66
Upside: +91.61%
Feb 8, 2024
Maintains: Buy
Price Target: $313 → $350
Current: $277.29
Upside: +26.22%
Feb 7, 2024
Reinstates: Buy
Price Target: $81
Current: $3.06
Upside: +2,547.06%
Jan 31, 2024
Maintains: Buy
Price Target: $442 → $559
Current: $489.10
Upside: +14.29%
Sep 13, 2023
Downgrades: Neutral
Price Target: $5
Current: $4.98
Upside: +0.40%
Aug 15, 2023
Maintains: Neutral
Price Target: $4.5 → $5
Current: $12.25
Upside: -59.18%
Jun 23, 2023
Maintains: Buy
Price Target: $188 → $215
Current: $53.79
Upside: +299.70%
Mar 2, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.83
Upside: +61.17%
Mar 2, 2023
Maintains: Buy
Price Target: $35 → $31
Current: $1.45
Upside: +2,037.93%
Feb 24, 2023
Maintains: Overweight
Price Target: $257 → $225
Current: $259.54
Upside: -13.31%
Nov 14, 2022
Initiates: Neutral
Price Target: $22
Current: $1.24
Upside: +1,681.38%
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Nov 10, 2022
Maintains: Neutral
Price Target: $60 → $30
Current: $5.00
Upside: +500.00%
Nov 10, 2022
Maintains: Buy
Price Target: $25 → $14
Current: $0.89
Upside: +1,474.80%
Nov 9, 2022
Maintains: Neutral
Price Target: $8 → $9
Current: $5.50
Upside: +63.64%
Nov 9, 2022
Downgrades: Neutral
Price Target: $16 → $3
Current: $1.25
Upside: +140.00%
Nov 4, 2022
Downgrades: Sell
Price Target: $15 → $12
Current: $14.71
Upside: -18.42%
Nov 3, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $1.64
Upside: +265.85%
Oct 28, 2022
Maintains: Neutral
Price Target: $39 → $43
Current: $46.87
Upside: -8.26%
Aug 19, 2022
Maintains: Sell
Price Target: $40 → $60
Current: $4.15
Upside: +1,345.78%
May 24, 2022
Maintains: Sell
Price Target: $3 → $2
Current: $1.43
Upside: +39.86%
May 24, 2022
Maintains: Sell
Price Target: $125 → $100
Current: $6.16
Upside: +1,523.38%
May 12, 2022
Maintains: Neutral
Price Target: $48 → $28
Current: $7.90
Upside: +254.65%
Mar 4, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.31
Upside: +9,454.14%
Mar 19, 2020
Maintains: Neutral
Price Target: $57 → $50
Current: $88.17
Upside: -43.29%
Mar 17, 2020
Initiates: Neutral
Price Target: $45
Current: $11.21
Upside: +301.43%